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Abstract
Background The diagnostic significance of the atopy patch test for the management of dermatitis possibly triggered
by aeroallergens is still controversial. However, sufficiently large studies with routinely tested standardized aeroallergen
patch test preparations in dermatitis patients are lacking.
Objective To evaluate the reaction frequency and the reaction profiles of 10 until mid-2015 commercially available,
standardized aeroallergen patch test preparations of the ‘Stallerpatch’ test series (Stallergenes, Antony Cedex, France)
in a large multicentre patient cohort.
Methods A retrospective data analysis of patients with suspected aeroallergen-dependent eczematous skin lesions
was performed, who were patch tested in 15 Information Network of Departments of Dermatology-associated clinics
between 2000 and 2015. Patients were stratified according to their atopic dermatitis (AD) status.
Results The study group included 3676 patients (median age 41 years, 34.8% males, 54.5% AD). The most common
aeroallergens causing positive patch test reactions were Dermatophagoides pteronyssinus (19.6%), Dermatophagoides
farinae (16.9%), birch (6.2%), timothy grass (6.0%), cat dander (5.4%), mugwort (4.9%) and dog dander (4.6%). Reac-
tions to other pollen allergen preparations, that is 5 grasses (3.2%), cocksfoot (2.1%) and plantain (1.6%), were less
common. Positive patch test reactions to aeroallergens were consistently more frequent in patients with AD. These
patients showed proportionally less dubious, follicular, irritant and weak positive reactions. Independent of AD status, a
patient history of past or present allergic rhinitis was associated with an increased chance of a positive aeroallergen
patch test reaction to pollen allergens.
Conclusion The aeroallergen patch test is a useful add-on tool in clinical routine, especially in patients with AD
and/or respiratory allergy. A patch test series comprising Dermatophagoides pteronyssinus, Dermatophagoides fari-
nae, birch, timothy grass, cat dander and mugwort seems to be suitable. Controlled studies with specific
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provocation and elimination procedures are required to further evaluate the diagnostic significance of the proposed
screening series.
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Introduction
Intact protein allergens, which include both a wide variety of
aeroallergens and food allergens, can cause, maintain or exacer-
bate skin diseases such as various types of contact dermatitis or
atopic dermatitis (AD).1–6 The first documented patch tests with
aeroallergens in different groups of dermatitis patients were per-
formed by Rostenberg and Sulzberger7 in 1937. In 1982, Mitchell
et al.8 described in more detail that aeroallergen patch test prepa-
rations such as Dermatophagoides (D.) pteronyssinus antigen P1,
which normally cause allergic reactions of the immediate type,
can also lead to late eczematous skin reactions when applied to
the skin of atopic patients for 48 h. They found that a prolonged
epicutaneous application of aeroallergens could cause an exacer-
bation of the existing atopic skin disease. This finding marked
the beginning of the development of the 1989 modified patch test
called ‘atopy patch test’ by Ring et al.,9 which was further stan-
dardized and validated, and has since been used predominantly,
though not exclusively,10 for diagnosing eczema-worsening by
aeroallergens or food allergens in patients with AD.11–17
The diagnostic significance of aeroallergen patch testing for the
evaluation of triggering factors of eczema in consecutive patients
is still controversial.7,18–21 However, there is probably an underes-
timation of the prevalence of aeroallergen sensitization that
causes, maintains or exacerbates eczematous skin lesions.2,22 Ulti-
mately, the identification and elimination of responsible aeroaller-
gens, exemplarily with regard to house dust mites (HDMs),23
have been found to be a crucial prerequisite for disease treatment
that can result in marked and sustainable improvement of the
skin symptoms.19,24,25 Thus, there is an ongoing need for research
on the routine use of patch testing in larger numbers of patients
with suspected aeroallergen-triggered dermatitis.25–28
The present retrospective multicentre study aimed to evaluate
the reaction frequency and diagnostic significance of 10 formerly
commercially available and biologically standardized29 aeroallergen
patch test preparations (‘Stallerpatch’; Stallergenes, Antony Cedex,
France; Table 1) in 3676 patients undergoing standard patch test-
ing for suspected allergic contact dermatitis and in which an
involvement of aeroallergens in the skin lesions was additionally
assumed. To the best of our knowledge, studies with a comparably
large number of dermatitis patients and standardized aeroallergen
patch test preparations are still lacking, even though the atopy
patch test methodology has been evaluated in several hundred
patients with AD.30 As a secondary aim, aeroallergen patch test
reaction profiles, that is irritant (‘IR’), follicular (‘f’), doubtful
(‘?+’), weak (‘+’) and strong positive reactions (‘++’ and ‘+++’),
were described and analysed by use of the reaction index (RI)31
and the positivity ratio (PR).32 As of now, data on these evaluation
parameters of aeroallergen patch test preparations have also been
missing, an exception being Brasch et al.,20 who reported a RI of
0.76 for the Dermatophagoides mix 20% in petrolatum (pet.; Che-
motechnique Diagnostics, Vellinge, Sweden).
Methods
Study design
For this retrospective multicentre data analysis, we retrieved
patch test data of 15 IVDK (‘Information Network of
Table 1 Aeroallergens of the patch test series ‘Stallerpatch’†
Test allergen Concentration
standardized in biologic unit29
Vehicle
Mites
D. farinae 200 IR/mL pet.
D. pteronyssinus 200 IR/mL pet.
Epithelia
Cat dander 200 IR/mL pet.
Dog dander 200 IR/mL pet.
Weed pollen
Mugwort 200 IR/mL pet.
Plantain 500 IC/mL pet.
Tree pollen
Birch 200 IR/mL pet.
Grass pollen
Cocksfoot 200 IR/mL pet.
Timothy grass 200 IR/mL pet.
5 grasses 200 IR/mL pet.
†Stallerpatch, distributed by Stallergenes (Antony Cedex, France) until 31
July 2015.
D., Dermatophagoides; IC, index of concentration; IR, index of reactivity;
pet., petrolatum.
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Departments of Dermatology’)-associated clinics from the IVDK
database.33
Data collection and management Patients’ histories including
indications for patch testing, clinical data and patch test results
of all patients patch tested in the participating clinics are docu-
mented in a standardized way, recorded in local databases and,
after pseudonymization, transmitted to the IVDK central office
at the University of G€ottingen, twice a year.34,35 Data on skin
prick tests, intradermal skin tests and IgE tests are not recorded
in the IVDK data documentation system and can therefore not
be analysed.
Patient selection
Between 2000 and 2015, a total of 59 174 dermatitis patients
(median age 50 years, range 5–85 years; 21 732 males) were
consecutively patch tested in the 15 IVDK-associated clinics
with the DKG baseline series and relevant supplements. In 3676
patients (median age 41 years, range 6–80 years; 1279 males),
patch tests with aeroallergen preparations from the Stallerpatch
(Table 1) were simultaneously performed on the macroscopi-
cally normal-appearing skin of the back. Indication for aeroal-
lergen patch testing was the suspicion of aeroallergen-
dependent skin lesions, independent of the type of dermatitis.
This subcohort of patients formed the study group for the pre-
sent analysis.
Atopy patch testing with aeroallergens
Patch testing and evaluation of reactions were performed
according to DKG guidelines.36,37 For this data analysis, patch
test reactions on D3 were taken into account. In a few excep-
tional cases (<5%), when a reading was performed on D4 instead
of D3, this reading was selected. Readings coded as ‘+’, ‘++’ or
‘+++’, that is, positive reactions, according to the ICDRG
(‘International Contact Dermatitis Research Group’) scoring
system,38 with erythema, infiltration, papules and/or (coalesc-
ing) vesicles were rated as positive in dichotomized analyses if
not otherwise indicated. Aeroallergen patch test preparations
were manufactured and marketed by Stallergenes until 31 July
2015. Patch test exposure time was 48 h in 88.6% of patients
(n = 3258) and 24 h in 11.4% of patients (n = 418). With only
a few exceptions (n = 167 patients, 4.5%), depending on the
applicable clinic standard, large (inner diameter 12 mm;
n = 2810 patients, 76.4%) and small (inner diameter 8 mm;
n = 699 patients, 19.0%) Finn Chambers on Scanpor tape
(Epitest Ltd Oy, Tuusula, Finland) were used as test chambers.
In the exceptional cases, IQ ChambersTM(Chemotechnique Diag-
nostics) were used. As an irritant control, sodium lauryl sulphate
(SLS) 0.25% in water was additionally tested in 2717 patients
(73.9%).39 An irritant reaction to SLS generally indicates
increased skin irritability of the patch test site at the time of test-
ing,40 meaning that doubtful or weak positive reactions to
allergen patch test preparations are more likely to be irritant and
not allergic in nature.
Statistical analysis
For descriptive purposes, we report categorical variables as abso-
lute and relative frequencies and continuous variables as the
median and range (minimum, maximum). The statistical signifi-
cance (P < 0.05) of differences in demographic and clinical
characteristics of disjunct patient groups was determined by
non-overlapping 95% confidence intervals (CIs). Non-overlap-
ping of 95% CIs was also used for assessing significance of differ-
ences in crude sensitization frequencies. We stratified for AD.
Patients were classified as past or present AD patients based on
common diagnostic criteria.41
To assess the reaction profiles – and thus diagnostic accuracy
– of aeroallergen patch test preparations, we used the RI31,42 in
combination with the PR.32 Non-overlapping 95% CIs were
used for the comparison of RIs and PRs. Patch test preparations
with a negative RI and a PR of ≥ 80% have a comparably low
diagnostic accuracy as far as identification of true allergic reac-
tions is concerned.32
Beyond atopic dermatitis, occurrence of positive patch test
reactions to aeroallergens may be influenced by other clinical
patient characteristics and by methodological aspects. In order
to estimate the impact of these factors on the aeroallergen patch
test outcome, we performed logistic regression analyses with
positive aeroallergen patch test reactions as target (dependent)
variables and 7 dichotomized explanatory (independent) vari-
ables. These were ‘past or present allergic rhinitis’ (AR), ‘past or
present allergic asthma’ (AA), ‘dermatitis in air-exposed skin
areas (face, neck, forearms, hands)’ (AEA), ‘polysensitization,
meaning sensitization to three or more independent contact
allergens of the DKG baseline series’ (POLY),43 ‘irritant patch
test reaction to SLS’ (SLS), ‘patch test exposure time of 2 days’
(E2D) and ‘use of large Finn Chambers’ (LFC). The logistic
regression model used was assessed for goodness of fit by the
Hosmer–Lemeshow test (P > 0.05).44 Results are presented as
odds ratio (OR) estimates with 95% CIs (profile likelihood
method).
Data were managed and analysed with the statistical software
package SAS (SAS Institute, Cary, NC, USA), version 9.4.
Ethical approval
The amended study protocol was subjected to review and
approved by the ethics committee of the Medical Faculty of the
Ruhr University Bochum (registration no. 15–5199; first positive
vote dated 25 February 2015; amendment dated 20 July 2016).
Results
Routinely collected patch test data from 12 dermatology clinics
in Germany and 3 dermatology clinics in Switzerland were
included in the study.
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Patients’ demographics and clinical characteristics
Demographic and clinical characteristics according to the
MOAHLFA index45 of all patch tested patients are shown in
Table 2. Patients of the study group (n = 3676; 6.2%), who were
patch tested with aeroallergens, showed a higher proportion of
women and were remarkably younger and more likely to have a
past or present history of AD and a facial dermatitis than the
vast majority of patients (n = 55 498; 93.8%) who had under-
gone conventional patch tests with contact allergens, but not
with aeroallergens. The last two observations will at least in part
be due to the indication for atopy patch testing with aeroaller-
gens. When the study group was further stratified by AD status,
there was a fairly uniform distribution of the characteristics in
both subgroups, except that the patients with AD were remark-
ably younger.
Aeroallergen patch test results
In the study group, positive patch test reactions to D. pteronyssi-
nus (19.6%, 95% CI: 18.3–21.0%) and D. farinae (16.9%, 95%
CI: 15.6–18.3%) were most frequently observed, followed by
positive patch test reactions to birch (6.2%, 95% CI: 5.4–7.1%),
timothy grass (6.0%, 95% CI: 5.1–6.9%), cat dander (5.4%, 95%
CI: 4.7–6.2%), mugwort (4.9%, 95% CI: 4.2–5.7%), dog dander
(4.6%, 95% CI: 3.6–5.8%), 5 grasses (3.2%, 95% CI: 2.2–4.5%),
cocksfoot (2.1%, 95% CI: 1.3–3.3%) and plantain (1.6%, 95%
CI: 1.0–2.4%).
Table 3 shows the distribution of reactions to aeroallergens
in the study group stratified by past or present AD. Crude per-
centages of positive reactions, RIs and PRs are delineated. In
both subgroups, positive reactions were most frequently
observed to the HDMs. Without exception, the relative reaction
frequencies in the patient subgroup with AD were higher,
although not significant for plantain, cocksfoot and 5 grasses.
These three allergens generally presented the lowest absolute
and relative reaction frequencies. Of all aeroallergen patch test
preparations, RIs were lower and PRs were higher in the
patients without AD, which may indicate that a considerable
proportion of the doubtful and weak positive reactions in this
subgroup of patients are irritant, and not allergic, reactions.
This phenomenon was particularly pronounced in cat dander
and pollen of mugwort, plantain, birch, cocksfoot, timothy
grass and 5 grasses.
Distribution of the explanatory variables used in the logistic
regression analyses in both subgroups is shown in Table 4. Ato-
pic respiratory diseases (AR and/or AA) and irritant patch test
reactions to SLS were significantly more common in the patient
group with AD. In contrast, involvement of air-exposed skin
areas, polysensitization and patch test exposure time of 2 days
were quite equally distributed. In the patient group without AD,
large Finn Chambers were used somewhat more frequently.
Stratified by AD, ORs as results of multivariate logistic regres-
sion analyses are given in Tables S1 and S2, with positive aeroal-
lergen patch test reactions as target variables and the 7 above-
mentioned items as explanatory variables. In addition, ORs as
results of univariate calculations are displayed to show the influ-
ence of every single explanatory variable, without adjusting for
the others. In the subgroup of patients with AD (Table S1), the
use of large Finn Chambers or patch test exposure for 2 days
exhibited the strongest impact of all independent variables in all
aeroallergens analysed, with ORs ranging from 3.31 to 9.44 and
from 1.76 to 3.62, respectively. Allergic rhinitis significantly
increased the chance of a positive aeroallergen patch test reac-
tion to mugwort, birch and timothy grass, with ORs ranging
from 1.88 to 2.77. In contrast, allergic asthma did not increase
the chance of a positive aeroallergen patch test reaction. Polysen-
sitization to three or more haptens predisposed to positive patch
test reactions to cat dander and birch. Increased skin irritability
as indicated by a positive (irritant) patch test with SLS increased
Table 2 Demographic and clinical characteristics according to the MOAHLFA index† of patients patch tested with the DKG baseline ser-
ies and relevant supplements in 15 IVDK-associated clinics between 2000 and 2015, stratified by aeroallergen patch test and stratified by
past or present AD; total number of patients = 59 174
Patients Aeroallergen patch test not
performed
Aeroallergen patch test
performed
Aeroallergen patch test
performed; AD
Aeroallergen patch test
performed; no AD
Total tested
Parameters
55 498 3676 2005 1671
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
M 20 453 36.9 (36.5, 37.3) 1279 34.8 (33.3, 36.4) 677 33.8 (31.7, 35.9) 602 36.0 (33.7, 38.4)
O 9062 16.3 (16.0, 16.6) 577 15.7 (14.5, 16.9) 272 13.6 (12.1, 15.1) 305 18.3 (16.4, 20.2)
A 10 315 18.6 (18.3, 18.9) 2005 54.5 (52.9, 56.2) 2005‡ 0‡
H 15 290 27.6 (27.2, 27.9) 999 27.2 (25.7, 28.6) 517 25.8 (23.9, 27.8) 482 28.8 (26.7, 31.1)
L 5351 9.6 (9.4, 9.9) 74 2.0 (1.6, 2.5) 32 1.6 (1.1, 2.2) 42 2.5 (1.8, 3.4)
F 8543 15.4 (15.1, 15.7) 1167 31.7 (30.2, 33.3) 640 31.9 (29.9, 34.0) 527 31.5 (29.3, 33.8)
A 39 436 71.1 (70.7, 71.4) 1927 52.4 (50.8, 54.0) 808 40.3 (38.1, 42.5) 1119 67.0 (64.7, 69.2)
†MOAHLFA index: ‘M’ male, ‘O’ occupational dermatitis, ‘A’ atopic dermatitis (past or present), ‘H’ hand dermatitis, ‘L’ leg dermatitis, ‘F’ face dermatitis, ‘A’
age ≥ 40 years. ‡By stratification.
AD, atopic dermatitis; CI, confidence interval; DKG, German Contact Dermatitis Research Group; IVDK, Information Network of Departments of Dermatology.
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the chance of a positive aeroallergen patch test reaction to mug-
wort and cat dander, and, most prominently, to dog dander.
Remarkably, dermatitis involvement of air-exposed skin areas
did not significantly increase the chance of a positive aeroaller-
gen patch test reaction to any of the aeroallergens listed. In the
subgroup of patients without AD (Table S2), fewer significant
ORs were found. Patients with allergic rhinitis had a significantly
increased chance of a positive aeroallergen patch test reaction to
both HDMs, mugwort and birch, while allergic asthma, dermati-
tis involvement of air-exposed skin areas and polysensitization
to three or more haptens had no significant impact. Patients
reacting to SLS had an increased chance of reacting to birch in
the aeroallergen patch test. Aeroallergen patch test exposure for
2 days and the use of large Finn Chambers, respectively,
increased the chance of a positive test reaction to both HDMs.
The latter explanatory variable also increased the chance of a
positive test reaction to mugwort.
Discussion
This retrospective multicentre study investigated, for the first
time, the reaction frequency to a standardized patch test series
with aeroallergens in a sufficiently powered cohort. We took a
closer look at the study population and factors most likely influ-
encing the patch test outcome to interpret results. Our findings
revealed that the most frequent aeroallergen group causing posi-
tive patch test reactions was by far HDM, followed by pollen and
pet dander.11 In line with other studies,11,12,46,47 we could not
observe a significant positive association between eczema in
Table 3 Patch test results based on reactions at D3 (or D4 in exceptional cases) in 3676 patients tested with aeroallergens from the
patch test series ‘Stallerpatch’, stratified by past or present AD
Test allergen n tested n negative ?+ f + ++ +++ IR % crude positive (95% CI) RI (95% CI) PR [%] (95% CI)
Perennial
D. farinae
with AD 1443 1079 67 7 221 60 8 1 20.0 (18.0, 22.2) 0.6 (0.5, 0.7) 76.5 (71.1, 81.2)
without AD 1463 1157 68 24 168 33 2 11 13.9 (12.1, 15.8) 0.3 (0.2, 0.4) 82.8 (76.8, 87.7)
D. pteronyssinus
with AD 1964 1441 66 17 329 93 12 6 22.1 (20.3, 24.0) 0.7 (0.6, 0.7) 75.8 (71.5, 79.8)
without AD 1643 1262 73 25 230 43 1 9 16.7 (14.9, 18.6) 0.4 (0.3, 0.5) 83.9 (79.0, 88.1)
Cat dander
with AD 1988 1776 42 3 133 26 4 4 8.2 (7.0, 9.5) 0.5 (0.4, 0.7) 81.6 (74.8, 87.2)
without AD 1658 1565 36 15 33 1 1 7 2.1 (1.5, 2.9) 0.2 (0.4, 0.1) 94.3 (80.8, 99.3)
Dog dander
with AD 794 728 8 0 43 14 1 0 7.3 (5.6, 9.3) 0.8 (0.6, 0.9) 74.1 (61.0, 84.7)
without AD 702 683 6 0 11 0 0 2 1.6 (0.8, 2.8) 0.2 (0.3, 0.6) 100 (71.5, 100)
Seasonal
Mugwort
with AD 1743 1568 40 7 108 15 2 3 7.2 (6.0, 8.5) 0.4 (0.3, 0.6) 86.4 (79.1, 91.9)
without AD 1494 1408 39 6 33 1 0 7 2.3 (1.6, 3.2) 0.2 (0.4, 0.0) 97.1 (84.7, 99.9)
Plantain
with AD 673 648 9 0 11 3 1 1 2.2 (1.3, 3.6) 0.2 (0.2, 0.6) 73.3 (44.9, 92.2)
without AD 591 579 5 0 4 1 0 2 0.8 (0.3, 2.0) 0.2 (0.7, 0.4) 80.0 (28.4, 99.5)
Birch
with AD 1776 1563 50 9 127 21 1 5 8.4 (7.1, 9.8) 0.4 (0.3, 0.5) 85.2 (78.5, 90.5)
without AD 1497 1391 43 6 47 6 0 4 3.5 (2.7, 4.6) 0.0 (0.2, 0.2) 88.7 (77.0, 95.7)
Cocksfoot
with AD 449 424 10 0 12 3 0 0 3.3 (1.9, 5.5) 0.2 (0.2, 0.6) 80.0 (51.9, 95.7)
without AD 441 427 8 0 4 0 0 2 0.9 (0.2, 2.3) 0.4 (0.9, 0.0) 100 (39.8, 100)
Timothy grass
with AD 1449 1271 35 7 109 21 4 2 9.2 (7.8, 10.9) 0.5 (0.4, 0.6) 81.3 (73.7, 87.5)
without AD 1319 1239 38 7 30 1 0 4 2.4 (1.6, 3.3) 0.2 (0.4, 0.0) 96.8 (83.3, 99.9)
5 grasses
with AD 577 538 13 0 23 2 0 1 4.3 (2.8, 6.3) 0.3 (0.0, 0.6) 92.0 (74.0, 99.0)
without AD 400 386 5 0 6 0 0 3 1.5 (0.6, 3.2) 0.1 (0.7, 0.4) 100 (54.1, 100)
AD, atopic dermatitis; CI, confidence interval; D, day; D., Dermatophagoides; f, follicular reaction (considered to be doubtful); IR, irritant reaction; PR, positivity
ratio; RI, reaction index; ?+, doubtful reaction.
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typical air-exposed skin areas and a positive aeroallergen patch
test result, but this does not seem to be easily generalizable.14,48
On the one hand, the contradictory study situation on this point
could be explained by a selection bias in larger multicentre stud-
ies,11,12 that is patients with a predominantly air-exposed eczema
distribution pattern and patients with eczematous skin lesions
which exceeded the air-exposed areas are not separated in the
subgroup.14 On the other hand, it is our experience that some
patients also report the worsening or a flare-up of eczematous
lesions in non-air-exposed skin areas during the pollen season.
Patch tests with 5 grasses, cocksfoot and plantain seem to be dis-
pensable in the future. In broader routine use, the atopy patch
test with aeroallergens may be of diagnostic significance, espe-
cially in patients with AD and, independently of that, also in
patients with AR, which makes the name ‘atopy patch test’9 even
more adequate.
The present study showed once again that patch test reactions
to aeroallergens can also be observed in patients without AD,
although the frequency of these reactions is considerably lower
compared to AD patients.19,21,46,49 So far, however, the problem
of atopy patch testing with aeroallergens in patients without AD
has been insufficiently investigated and has shown contradictory
results. In contrast to our results, Brasch et al.20 reported in a sin-
gle-centre analysis that positive responses to the Der-
matophagoides mix did occur with similar frequency in patients
with and without AD, whereas other study groups had not
described a single positive patch test response to distinct aeroal-
lergens in patients without AD.15,16 An increased aeroallergen
responsiveness in patients with AD might be mediated by a com-
bination of increased epidermal penetration through the
impaired physical barrier and steady-state inflammation found
in, for example filaggrin (FLG) and/or hornerin (Hrnr) deficient
skin.50–52 The possible result is an increased access of aeroaller-
gens to Langerhans and inflammatory dendritic epidermal cells
with a selective upregulation of the Th2 immune response.
2,4,53,54
As patients with AD tend to have more frequent irritant or
false-positive reactions to commonly tested haptens,55–58 it was
of special importance to assess the reaction profiles of the dis-
tinct aeroallergen patch test preparations. Unexpectedly, consid-
erably more unwanted and weak positive reactions were found
in the patient subgroup without AD. However, this is in line
with previous study results of Seidenari et al.,19 where non-AD
patients showed a lower patch test reaction strength to two Der-
matophagoides mixes at different concentrations than AD
patients. One explanation could be that patients with epidermal
deficiency of, for example, FLG and/or Hrnr exhibit not only
more, but also a stronger patch test reaction to aeroallergens.50,57
Thus, these results speak against the generalizing interpretation
of aeroallergen patch test reactions as irritant or unspecific in
AD patients,59 even though there is no morphological way to
distinguish a weak irritant reaction from a weak allergic
reaction.60,61
Largely independent of AD status, our data confirm previous
results suggesting a role for patch testing HDM and pollen aller-
gens in patients with respiratory allergy,19,62 especially when
there is a positive history for AR. It is known that patients with
AR or AA and negative IgE tests can be detected by an aeroaller-
gen patch test.22,63 The allergen that is most often positive in this
‘intrinsic’ form of respiratory disease manifestation is HDM.
The underlying pathophysiology is elusive. Hypothetically, as
recently suggested for FLG loss-of-function mutations,64 a path-
way that unites the airways and the skin could be responsible for
primary respiratory sensitization to aeroallergens being demon-
strated by patch testing. It is noteworthy that this sensitization
pathway for sesquiterpene lactones, which are detected in the
conventional patch test and possibly mediated via inhalation of
airborne pollen or mucosal contact of airborne plant tri-
chomes,65 has already been discussed for some time.66,67 How-
ever, results of no correlation between a positive aeroallergen
patch test outcome and a respiratory allergy have also been
Table 4 Seven additional factors† possibly associated with the aeroallergen patch test outcome, and used in logistic regression analy-
ses, stratified by past or present AD; total number of patients = 3676
Patients Aeroallergen patch test performed; AD Aeroallergen patch test performed; no AD
Total tested 2005 1671
Parameters n % (95% CI) n % (95% CI)
AR 1030 51.4 (49.2, 53.6) 342 20.5 (18.6, 22.5)
AA 385 19.2 (17.5, 21.0) 108 6.5 (5.3, 7.8)
AEA 1206 60.1 (58.0, 62.3) 1054 63.1 (60.7, 65.4)
POLY 221 11.0 (9.7, 12.5) 181 10.8 (9.4, 12.4)
SLS 300 (out of 1449) 20.7 (18.6, 22.9) 202 (out of 1268) 15.9 (14.0, 18.1)
E2D 1782 88.9 (87.4, 90.2) 1476 88.3 (86.7, 89.8)
LFC 1495 74.6 (72.6, 76.5) 1315 78.7 (76.7, 80.6)
†Factors: ‘AA’ allergic asthma (past or present), ‘AEA’ air-exposed skin areas (face, neck, forearms, hands) involved, ‘AR’ allergic rhinitis (past or present),
‘E2D’ patch test exposure time of 2 days, ‘LFC’ use of large Finn Chambers, ‘POLY’ polysensitization to three or more independent allergens (haptens) of
the DKG baseline series, ‘SLS’ irritant patch test reaction to sodium lauryl sulphate 0.25% aqueous.
AD, atopic dermatitis; CI, confidence interval.
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reported.6,16,20,48 Nevertheless, it may be that, if allergy diagnos-
tics is not limited to skin prick tests and IgE tests but enhanced
by atopy patch tests with aeroallergens, additional cases of AR
are detected.
It is occasionally assumed that there are some unidentified
factors that may favour a rather unspecific response to aeroaller-
gens.20 This aspect was covered in our study by considering SLS
reactivity and polysensitization to typical contact allergens.
However, polysensitization to haptens, which was evenly dis-
tributed between AD and non-AD patients,68,69 did not prove to
be a relevant surrogate marker for a general inherent susceptibil-
ity to aeroallergen sensitization. With SLS reactivity, the situa-
tion was similar. Patients who reacted to the SLS irritation on
the skin were not generally prone to react to aeroallergens, in line
with previous studies.12–14 In summary, it seems unlikely that
the skin reactions to the aeroallergen patch test are mainly
unspecific. However, it should be noted that mites and pollen
contain major allergens with proteolytic enzyme activity which
may cause potentially irritant patch test reactions and may
therefore be responsible for an unknown number of false-posi-
tive reactions, especially in AD patients with higher positivity
rates.46–48,63,70
In the logistic regression analyses, the methodological aspects
of a larger test chamber or a longer occlusion time turned out
to be the strongest association factors for a positive aeroallergen
patch test outcome. Varying among studies, for aeroallergens
both small20,62,71–73 and large Finn Chamber sizes11,12,19,48
have been used. According to Darsow,25,30 an intraindividual
comparison using D. pteronyssinus, cat dander as well as birch
and grass pollen allergens (200 IR/mL; Stallergenes) showed
‘better’ results with large Finn Chambers. So far, however,
there are no published data and explanations that would justify
the use of a particular test chamber size.60 On the one hand, a
larger occluded test area could facilitate aeroallergen penetra-
tion and boost true-positive reactions, and30,74 on the other
hand, it could increase the rate of unspecific responses that
may be due to the proteolytic enzyme activity of aeroallergen
patch test preparations.19 Our results are also consistent with
the findings of Darsow et al.,11 where the 48-h occlusion time
led to much more positive results than the 24-h occlusion time.
One may speculate whether this reflects the high molecular
weight along with a slow skin penetration of the aeroallergens
compared to haptens.75–77
Limitations
There are limitations concerning the interpretation of our
results. In most cases, we do not have reliable information about
clinical relevance. However, clinical practice frequently reports
positive aeroallergen patch test results of unknown relevance,
because the patients’ awareness of aeroallergen-specific exacerba-
tion of eczema (e.g. seasonal ‘flare-up’ or ‘summer erup-
tion’)13,78 is often poor, especially in perennial aeroallergens,
and there is no gold standard for identifying of such eczema trig-
gers.11,16,25,28,74,79 Only resolutely realised aeroallergen-specific
avoidance strategies3,5,6,24,80,81 can help evaluating the relevance
of positive aeroallergen patch tests on the basis of a clinical
improvement.28
We did not record any skin prick test data or IgE test data that
we could correlate with our aeroallergen patch test results. How-
ever, although a positive atopy patch test reaction is frequently
observed in patients with corresponding immediate-type sensiti-
zations in skin prick tests or IgE tests,11,12,16,82,83 positive skin
prick tests or allergen-specific IgE levels were found to be non-
predictive for the result of the atopy patch test.28,84 In addition,
it was repeatedly reported that a subgroup of patients who did
not have a positive skin prick test or elevated specific IgE had a
positive atopy patch test.11,12,16,19,22,63,83 The different compart-
mentalization of the immune cells in the body is discussed as
one possible cause for these test method-dependent results. Fur-
thermore, the atopy patch test seems to provide additional infor-
mation on eczematous skin inflammation.
Finally, against the background of the ETFAD (‘European
Task Force on Atopic Dermatitis’) recommendations on the
implementation of the atopy patch test,25 one methodological
aspect needs to be addressed. Our readings are based on the
ICDRG scoring system38 for conventional patch testing, which
largely corresponds to the recommended ETFAD scoring sys-
tem for atopy patch testing.25 However, the revised ETFAD
scoring system offers one further option (‘++++’) to describe
the different morphology of positive patch test reactions, but
this was not relevant for our analyses, as all positive reactions
were summarized. Furthermore, clinically meaningful atopy
patch test results were also obtained with the ICDRG scoring
system.12,13,15,16,18,49,73,77,85
Conclusions
This large multicentre cohort study supports the widespread
perception that the atopy patch test with aeroallergens is a useful
clinically tool for assessing cutaneous delayed-type reactions to
protein allergens in patients with allergic skin diseases and respi-
ratory diseases, respectively.2,22,25,63,74 In the latter patients, the
atopy patch test may complement the routine diagnostic workup
of a suspected allergy to aeroallergens by means of a skin prick
test and/or IgE test.16 Finally, positive aeroallergen patch tests
are not limited to AD patients,10,19 as the originally proposed
name ‘atopy patch test’ suggests.9
Based on our results, reflecting a reaction frequency > 2% in
the patient subgroup without AD (Table 3), we propose a
reduced aeroallergen patch test series for the clinical routine
consisting of D. pteronyssinus, D. farinae, cat dander, mugwort,
birch and timothy grass, all 200 IR/mL in pet. However, con-
trolled studies with specific provocation4 and elimination proce-
dures23 in patients with positive and negative aeroallergen patch
test reactions would remain desirable to demonstrate the
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diagnostic significance of such a screening series for the clinical
course of the disease.21,79,81
Since mid-2015, there has been a large gap in the availability of
commercial aeroallergen patch test preparations on the European
market, which may lead to impaired disease management of
aeroallergen-related allergies, including patient education, specific
avoidance strategies and treatment decisions.3,22,63 Currently, only
one Dermatophagoides mix (D. pteronyssinus/D. farinae 50/50;
Chemotechnique Diagnostics) patch test preparation is commer-
cially available without marketing authorization in a 30% solution
in pet.,86 of which it has been assumed that its concentration is
probably too high.20,87 In order to generally overcome the restric-
tions on the availability of approved or marketable commercial
patch test preparations in Germany, the Paul-Ehrlich-Institute
has sent a first signal to allergen manufacturers and now grants
on request a fee reduction to one quarter for scientific advice,
new marketing authorizations, official batch release and the pro-
cessing of variation applications for ‘rare test allergens’.88 In
America, patient-specific prescriptions for atopy patch tests can
be fulfilled by the SmartPractice Allergen Bank compounding
pharmacy (Phoenix, AZ, USA). Prescribing physicians are pri-
marily allergists (Curt Hamann, SmartPractice, personal commu-
nication). Finally, due to the public interest also in ‘rare test
allergens’,88 the availability of commercial aeroallergen patch test
preparations should be revived by adequate cost-covering reim-
bursement to treating physicians,2,3 as high-quality, effective and
safe aeroallergen patch test preparations are considerably more
expensive than standardized hapten patch test preparations.74,82
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Supporting information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Odds ratios as results of multivariate logistic regres-
sion analyses with positive aeroallergen patch test reactions as
target variables and seven explanatory factors as independent
variables in patients with past or present atopic dermatitis.
Table S2. Odds ratios as results of multivariate logistic regres-
sion analyses with positive aeroallergen patch test reactions as
target variables and seven explanatory factors as independent
variables in patients without atopic dermatitis.
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